Nektar Therapeutics to Participate in Two Investor Conferences in March
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference in Boston (March 2-4) and Jefferies Biotech on the Beach Summit in Miami (March 9-11).
The TD Cowen presentation is webcast on Wednesday, March 4, 2026 at 9:10 a.m. ET with a replay available for 30 days; one-on-one meetings at Jefferies are available by request.
Positive
- None.
Negative
- None.
News Market Reaction – NKTR
In the Feb 25 session, NKTR gained 2.85%, reflecting a moderate positive market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Research collaboration | Positive | +3.5% | Collaboration with UCSF to study NKTR-0165 in multiple sclerosis models. |
| Feb 13 | Offering closed | Positive | +0.5% | Closing of $460M public offering with underwriters’ option fully exercised. |
| Feb 11 | Offering priced | Positive | +18.5% | Pricing of upsized $400M public offering to fund rezpegaldesleukin Phase 3. |
| Feb 10 | Proposed offering | Positive | +51.1% | Announcement of proposed $300M public offering under effective S-3ASR shelf. |
| Feb 10 | Clinical data update | Positive | +51.1% | REZOLVE-AD Phase 2b data showing durable efficacy and favorable safety. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including offerings and positive clinical data, has generally coincided with positive 24-hour price reactions.
Over recent months, Nektar reported positive Phase 2b REZOLVE‑AD data, multiple equity offerings, a liquidity update, and a new NKTR‑0165 research collaboration. These events, often tied to rezpegaldesleukin’s advancement toward Phase 3 and capital raises, saw 24-hour moves up to 51.07%. Today’s conference-participation news fits an investor-relations cadence rather than a major clinical, financing, or partnership catalyst, contrasting with earlier price-moving announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- TD Cowen 46th Annual Health Care Conference in
Boston on Wednesday, March 4, 2026 – webcast of the presentation to be available at 9:10 a.m. Eastern Time / 6:10 a.m. Pacific Time – link here - 2026 Jefferies Biotech on the Beach Summit in
Miami – March 9-11, 2026 – company management to be available for one-on-one meetings
The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. A replay of the presentation will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Nektar is headquartered in San Francisco,
For Investors:
Vivian Wu
628-895-0661
VWu@nektar.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577
For Media:
Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-march-302696266.html
SOURCE Nektar Therapeutics